Merck KGaA Profit Beats Estimates on Cost-Cutting

May 14 (Bloomberg) -- Merck KGaA, the German maker of cancer drug Erbitux, said first-quarter profit rose on higher-than-expected savings from a reorganization program, and forecast it will achieve 2014 targets a year ahead of schedule. Mark Barton reports on Bloomberg Television's "Countdown." (Source: Bloomberg)
Behind Workday's European Expansion Plans
42:46 - Workday Co-CEO Aneel Bhusri discusses the company's business strategy and enterprise market. He speaks on "Bloomberg West." (Source: Bloomberg)
  • Two Charts You Can't Miss on Markets Meltdown
  • Citi Expert Debunks the Chart of the Day
  • Fed at Jackson Hole: Readying a Rate Hike?